Oteseconazole, with the generic name oteseconazole and marketed under the brand name Vivjoa, is an oral capsule formulation primarily used as an azole antifungal medication.
Pluvicto, whose generic name is lutetium Lu 177 vipivotide tetraxetan, received FDA approval for its indicated use in adult patients with PSMA-positive mCRPC.
Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Ganaxolone, marketed under the brand name Ztalmy, is FDA approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in individuals aged 2 years and older.
Jul 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.